COMP <GO>
ZYME vs MRVI // EV/EBITDA & P/E VALUATION
Zymeworks Inc. (NASDAQ) VS. Maravai LifeSciences Holdings Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: ZYME 6
— MRVI 1
■ METRIC PARITY
LAST: $28.99 (+1.33%) • MKT CAP: $2.02B
valuation
—
LAST: $7.19 (-7.94%) • MKT CAP: $2.03B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZYME VS. MRVI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZYME | MRVI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 18.30% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.20% | -35.00% | +2.80 | ZYME | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.71% | -3.22% | +1.51 | ZYME | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 38.90% | -28.30% | +67.20 | ZYME | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 11.85 | 3.04 | +8.81 | ZYME | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 3/9 | +1.00 | ZYME | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.0 | 52.2 | +7.80 | ZYME | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.02B | $2.03B | -$11.8M | MRVI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZYME REV | MRVI REV | ZYME GROSS % | MRVI GROSS % | ZYME FCF | MRVI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $106.0M | $185.7M | — | 18.3% | -$34.5M | -$70.7M |
| FY 2024 | $76.3M | $259.2M | — | 41.8% | -$112.0M | -$22.2M |
| FY 2023 | $76.0M | $288.9M | — | — | -$118.3M | $126.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZYME // BETA —
MRVI // BETA —